Effectiveness and Safety of Deucravacitinib in Moderate-to-Severe Psoriasis: an Italian Multicenter Real-Life Study in the Lazio Region

Introduction: Psoriasis is a chronic, immune-mediated disease that significantly impacts patients’ quality of life. Deucravacitinib, an oral selective TYK2 inhibitor, has shown promising efficacy and safety in phase 3 trials, but real-world evidence remains limited. Objective: To evaluate the eff...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Annunziata Dattola, Francesca Paola Sasso, Giorgio Marotta, Giuseppe Rizzuto, Nicoletta Bernardini, Severino Persechino, Domenico Giordano, Diego Orsini, Viviana Lora, Anna Maria Mazzotta, Gianluca Pagnanelli, Gaia Moretta, Vincenzo Roberti, Alessandro Giunta, Chiara Cattani, Alessandra D'Amore, Clara De Simone, Antonio Giovanni Richetta, Elena Campione, Giacomo Caldarola
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Mattioli1885 2026-01-01
Serie:	Dermatology Practical & Conceptual
Ämnen:	Psoriasis, Deucravacitinib, Tyrosine Kinase 2 Inhibitors, Treatment Outcome, Real-World Evidence
Länkar:	https://www.dpcj.org/index.php/dpc/article/view/7116
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!